Immunic's lead drug fails to impress in 2 separate trials — and it's blaming some of its woes on the pandemic

The pandemic has posed a serious challenge to the way drugmakers do business, which has made it an easy scapegoat for clinical trial duds. Once looking to solve Covid-19, Immunic’s lead drug has now flopped one study and failed to impress in another — is it fair to blame the pandemic for that?